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Abstract
Aim
Evaluation of an external color coded perfusion quantification software with CEUS for the
post-interventional success control following TACE in patients with HCC.
Material and methods
31 patients (5 females, 26 males, age range 34–82 years, mean 66.8 years) with 59 HCC
lesions underwent superselective TACE using DSM Beads between 01/2015 and 06/2018.
All patients underwent CEUS by an experienced examiner using a convex multifrequency
probe (1–6 MHz) within 24 hours following TACE to detect residual tumor tissue. Retrospec-
tive evaluation using a perfusion quantification software regarding pE, TTP, mTT, Ri and
WiAUC in the center of the lesion, the margin and surrounding liver.
Results
In all lesions, a post-interventional visual reduction of the tumor microvascularization was
observed. Significant differences between center of the lesion vs. margin and surrounding
liver were found regarding peak enhancement (867.8 ± 2416 center vs 2028 ± 3954 margin
p<0.005) and center 867.8 ± 2416 vs 2824 ± 4290 surrounding liver, p<0.0001)). However,
no significant differences were found concerning Ri, WiAuC, mTT and TTP.
Conclusion
CEUS with color- coded perfusion imaging is a valuable supporting tool for post-interven-
tional success control following TACE of liver lesions. Peak enhancement seems to be the
most valuable parameter.
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Introduction
Liver lesions are the sixth most common cancer (approximately 750,000 new cases per year)
and currently represent the third most common cause of cancer-related deaths worldwide.
Hepatocellular carcinoma (HCC) shows an increasing incidence and generates over 90% of all
primary hepatic cancers, thus representing a major healthcare problem [1].
HCC has a strong male predominance with an estimated male to female ratio of 2.4 [1].
Approximately 90% of HCCs are associated with known underlying risk factors. The most fre-
quent factors include chronic viral hepatitis (types B and C), alcohol intake and aflatoxin expo-
sure [2].
Hepatic cirrhosis is an important risk factor for HCC, commonly caused by chronic viral
hepatitis, alcohol, inherited metabolic diseases such as hemochromatosis or alpha-1-antitryp-
sin deficiency, and non-alcoholic fatty liver disease. All etiologic forms of cirrhosis may be
complicated by tumor formation, but the risk is higher in patients with hepatitis with 2–8%
per year [3]. Various published guidelines agree on a typical vascular pattern of HCC lesions,
being characterized by early arterial enhancement followed by contrast media wash-out begin-
ning in the venous phase [4–6]. Small tumor lesions < 1 cm often display no venous wash out
at all. The imaging modalities recommended for diagnosis of HCC include contrast enhanced
magnetic resonance imaging (MRI), multi-phase contrast enhanced computed tomography
(CT) and contrast enhanced ultrasound (CEUS). Current studies have shown a sensitivity for
detection of HCC of up to 91.1% for CEUS [7–9] up to 87.5% for CT [10] and up to 95.9% for
Gd-EOB-DTPA-Enhanced Liver MRI (Gadolinium ethoxybenzyl diethylenetriamine pentaa-
cetic acid) [11].
Depending on the local tumor extent, extrahepatic spread and the established degree of
liver damage, various therapeutic options are available for each stage. For early stage HCC sur-
gical resection [12], ablation [13] and transplantation [14] are recommended. Furthermore
trans-arterial chemoembolization (TACE) [15] is suggested for intermediate-stage HCC, sora-
fenib for advanced-stage HCC [16]. Finally, for terminal-stage HCC best supportive care is
advised [5].
TACE is commonly used in two settings, either in HCC unsuitable for resection or ablation
or liver transplantation as a bridge therapy [17]. The aim of TACE is to pad the tumor with a
chemotherapeutic drug (eg, doxorubicin, epirubicin, cisplatin, or mitomycin C) using a carrier
agent. Formerly, Lipiodol was used as the carrier agent, but this has been largely replaced by
drug-eluting beads, which are available in different sizes [18].
Aim of this study was the evaluation of an external color coded perfusion quantification
software with CEUS for the post-interventional success control following TACE in patients
with HCC.
Material and methods
Study design
From January 2015 until June 2018, 31 patients (26 males, 5 females, age 34–82 years, mean
62.8 years) with 59 HCCs, identified by characteristic imaging features or histopathology were
included in this retrospective study. Each patient underwent pre-interventional contrast-
enhanced computed tomography (CT) and liver specific contrast enhanced magnetic reso-
nance imaging (MRI) for detection and characterization of the liver lesions within 72 hours
prior to the intervention. The study was approved by the University medical Center Regens-
burg ethics Committee (reference number 15-104-0115).
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The therapeutic interventional procedure for each patient was a superselective trans-arterial
chemoembolization (TACE) using degradable starch microspheres (DSM; EmboCept S, Phar-
maCept, Germany) loaded with 50 mg Epirubicin (Famorubicin, Pfizer, USA). The indication
for a TACE was formed by an interdisciplinary tumor conference.
Each patient was examined using B- mode, Color Coded Doppler Sonography (CCDS),
Power Doppler and Contrast Enhanced Ultrasound (CEUS). Before the imaging procedures
were conducted, written informed consent was obtained from each patient for MRI, CT and
CEUS. Exclusion criteria of this study were contraindications for use of a contrast agent for
CT, MRI or CEUS, impaired renal function (creatinine >1.5 mg/dl, creatinine clearance < 30
ml/min), pre-existing strong allergic reactions and decompensated cardiac failure.
Imaging studies
Basic ultrasound examination. Within 24 hours following TACE, ultrasound was per-
formed by an experienced radiologist with national DEGUM stage III using a multifrequency
convex transducer (1–6 MHz, LOGIQ E9, GE Healthcare).
First, the whole liver was examined using B-mode sonography in sweep technique. Color
Coded Doppler Sonography (CCDS) and Power Doppler (PD) ultrasound were used to evaluate
macro vascularization. Flow parameters were adjusted to the lowest possible pulse repetition
frequency (PRF< 1000 Hz) and the best possible color imaging without blooming artifacts.
CEUS. Contrast enhanced ultrasound (CEUS) was performed after bolus injections of
1–2.4 ml of sulphur hexaflouride microbubbles (SonoVue, BRACCO, Italy) with a low
mechanical index (MI < 0.16) applying CEUS with amplitude modulation and pulse inversion
harmonic imaging (PIHI) technique. The contrast harmonic imaging technique (CHI) uses a
contrast-specific detection mode for real-time evaluation of the contrast-agent enhancement.
The complete data of the contrast-agent examination was recorded up to 5 min. The liver
microcirculation was evaluated continuously from an early arterial phase (beginning 15 sec.
after contrast application) until a late parenchymal phase (> 5 min.). The transducer was held
steadily on the post-embolisation defect of 1 minute to avoid repeated injection of contrast
media, afterwards the whole liver was examined in sweep technique to look for wash-out. The
first minute was documented a video clip. Afterwards single images were stored until the late
phase. All images were digitally stored in PACS.
Irregular enhancement in the periphery of the embolized area during early arterial phase,
ideally combined with a wash-out starting during portal venous phase was seen as a character-
istic criterion for residual HCC tissue. A uniform peripheral rim enhancement without wash-
out was considered as physiological postembolization reaction. Wedge-shaped, homogenous
arterial enhancement peripheral to the embolized area with progressively enhancing portal-
venous branching but without washout was defined as arterio-portal-venous shunt.
CEUS was performed within 24 hours prior and following the procedure.
CT/ MRI. Each patient received a pre- and post-interventional contrast-enhanced dual
source CT (ceCT) of the liver in arterial phase (25–35 sec), in portal-venous phase (70–90 sec)
and late phase (>120 sce) with bolus injection of iodic contrast-agent (100–130 ml Accupaque,
GE) (SOMATOM Definition Flash Siemens Healthcare, Erlangen Germany; collimation 5
mm with coronary and axial reconstructions). Before the treatment every patient received a
ceCT of the whole abdomen/ pelvis in portal-venous phase to exclude extrahepatic tumor
manifestation. Within 24 hours after the treatment only the liver was scanned in arterial and
portal-venous phase to exclude post-interventional complications.
An additional pre-interventional contrast-enhanced MRI (ceMRI) was performed (Skyra
3T, Siemens Healthcare, Erlangen, Germany), using T1/ T2 sequences, diffusion imaging with
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ADC as well as contrast-enhanced sequences after bolus injection of 15–35 ml liver specific
contrast agent (Gd-EOB-DTPA), (Primovist, Bayer, Schering Pharma AG, Germany) using
3D vibe sequences from arterial phase (20–25 sec) up to late phase.
For follow-up, patients received CEUS, MRI and CT scans according to the protocols men-
tioned above for up to 6 months.
Perfusion analysis. The digitally stored ultrasound loops were evaluated using a color
coded perfusion quantification software (VueBox, Bracco, Italy) on a separate computer.
DICOM loops were uploaded and opened in the VueBox platform (BRACCO, Italy) for
blinded and independent reading. VueBox is a color-coded off-line general-purpose perfusion
software for dynamic CEUS examinations, that uses automatic in-plane motion correction
[19]. Four parameters were calculated for each Region of interest (ROI) which included time
to peak (TTP), mean transit time (mTT), peak enhancement (pE), Wash-in Area Under the
Curve (WiAUC) and Rise (Ri). Flow parameters such as regional blood volume and regional
blood flow were calculated by the software and exported in a calculation protocol.
Regions of Interst (ROI) were manually placed in the center of the lesion, at the margins
and the surrounding liver tissue> 2cm distance. The VueBox screen is divided into four quad-
rants: in the upper left quadrant the original image with the ROIs is displayed, in the upper
right quadrant the corresponding parametric image is displayed, in the lower left quadrant the
corresponding time/intensity curves are shown in the color corresponding to the ROI in the
image above and in the lower right quadrant the respective numerical values of the selected
curve parameter is shown [20, 21] (image 2).
Imaging analysis
CEUS examinations and the perfusion analysis were read by two experienced radiologists in
consensus. For each modality, each observer recorded the diagnostic findings. Furthermore,
the image quality was documented on a four points scale: 1—excellent, 2—minor diagnostic
limitations, 3 –major diagnostic limitations, 4—non-diagnostic.
Imaging modalities were evaluated using the data analysis hard-/software of the ultrasound
system (LOGIQ E9, GE).
Statistical analysis
For data analysis, IBM-SPSS software (version 19.0, SPSS Inc., Chicago, USA) was used.
For calculation of the differences between the center of the lesion and the margins, the mar-
gins and the surrounding liver as well as the center of the lesion and the surrounding liver for
each parameter repeated measures ANOVA with Bonferroni post test was performed using
GraphPad Prism version 5.00 for Mac OS X, GraphPad Software, San Diego California USA
with alpha = 0.05 indicating statistically significant differences between groups.
Results
Lesions characteristics and tumor size
Each of the 59 tumor lesions showed an enhancement pattern consistent with hepatocellular
carcinoma (HCC) including arterial irregular hyperenhancement and portal venous washout
on CEUS. Also, the pre-interventional imaging techniques showed characteristics compatible
with HCC. All 31 patients underwent pre-interventional MRI using a liver specific contrast
agent (Primovist, Bayer HealthCare AG, Germany; 0.1 ml/kg body weight) and a pre-interven-
tional CT. Also, post-interventional CT scans were performed within 24 hours after the
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procedure to identify complications. During the 6 months follow-up, all patients with recur-
rent disease were correctly identified using CEUS.
The pre-interventional tumor sizes of the 59 lesions ranged from 9 mm up to 55 mm with a
mean size of 36 mm. The post-interventional defects sized from 11 mm to 55 mm with am
mean size of 31 mm. In all lesions, a post-interventional reduction of the tumor microvascular-
ization was observed.
Perfusion analysis and CEUS
In all 31 patients (100%) CEUS was viable. The image quality in all examinations was excellent
or had only minor diagnostic limitations (1–2 SD ± 0.372).
The data acquired for pE, WiAuC, mTT, TTP and Ri is shown in Table 1. No significant
differences between center of the lesion vs. margin, margins vs. surrounding liver and center
of the lesion vs. surrounding liver were found regarding WiAuC, mTT, Ri and TTP.
However, significant differences were found for pE center of lesion vs surrounding liver (p
<0.0001) and center of lesion vs margin of lesion (p< 0.005). No significant differences were
found for pE surrounding liver vs margin of lesion (Fig 1). The 95% confidence intervals (CI)
of difference were 1067 to 2845 for center vs. surrounding liver, -92.86 to 1685 for surrounding
liver vs. margin and -2049 to -271.4 for center vs. margin.
The perfusion software uses pseudo-colors to show vascularization. Hypervascularization is
shown in red and yellow shades (Fig 2). Devascularization is shown in blue and green colors.
In all cases there was a profound visual reduction of vascularization displayed as blueish and
greenish nuances (Figs 3 and 4).
Discussion
Whereas surgical resection and ablation are widely accepted for curative care, trans-arterial
chemoembolization remains the standard treatment option in patients with non-resectable
HCC or if an ablative technique is not possible. The long-term results regarding tumor recur-
rence and overall survival are favorable compared to best supportive care [22]. Assessment of
tumor response following interventional treatment is crucial for determination of treatment
efficiency and further strategies.
Postinterventional success control following TACE and ablative techniques can be better
evaluated by observing changes regarding the tumor vascularization rather than the size. Thus,
CEUS is a valuable method for follow-up as it allows a continuous display of the microvascu-
larization of a lesion [20, 23]. Previous CEUS studies have shown a sensitivity of 87–100% and
a specificity of 65–100% in detecting residual tumor after TACE [24, 25]. Moschouris et al.
used additionally perfusion quantification for HCC evaluation in both the pre- and post-
TACE setting monitoring a statistically significant decrease in perfusion index (PI) after TACE
[26].
Table 1. Mean ±SD of pE, WiAuC, mTT, TTP and Ri each in the center of the lesion, the margins and the periphery, collected within 24 h following TACE.
center (mean ± SD) margin (mean ± SD) Surrounding liver (mean ± SD)
pE 867.8 ± 2416 2028 ± 3954 2824 ± 4290
WiAuC 385.4 ± 1262 564.6 ± 954.9 1149 ± 4473
mTT 211.3 ± 195.0 184.1 ± 150.6 163.8 ± 157.1
TTP 24.15 ± 13.97 22.40 ± 11.70 20.93 ± 10.69
Ri 19.84 ± 13.51 18.08 ± 10.35 16.78 ± 9.91
https://doi.org/10.1371/journal.pone.0217599.t001
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The color coded perfusion software (VueBox) used in this study shows hyper enhancement
in yellow and red shades, whereas devascularized areas appear blue. By using ROIs in the cen-
ter of the lesion, the margins and the surrounding liver tissue the extent of devascularization
could be analyzed. The therapeutic success postulates a near complete devascularization of the
center of the malignant lesion as well as its border area. Nodular enhancement and irregular
regional enhancement pattern correlate with residual vital tumor. However, contrast enhance-
ment 24 hours after the ablation can either be evoked by reactive changes in terms of immu-
noresponses [27, 28] or remaining tumor. Thus, for TACE, the use of CEUS for follow-up
within 24 hours post-intervention would not change the diagnostic and therapeutic setting.
Previous studies have evaluated the perfusion parameters of gastrointestinal stoma tumors
(GIST) [29] and prostate cancer [30]. However, this is the first time that a perfusion software
was used for evaluation of the therapeutic success following TACE in HCC.
A critical point is, that the perfusion software often shows incomplete devascularization fol-
lowing TACE. Therefore, for establishing the clinical success, long- term follow-up is crucial.
In this study, we were able to analyze and compare various perfusion parameters including
peak enhancement, Wash-in area under the curve, mean transit time and time to peak in the
center of the lesion, its border area and the periphery for the first time.
Our study had some limitations. The study population was heterogeneous with regard to
the tumor sizes and the extent of liver cirrhosis. A further limitation is the still relatively small
number of patients and lesions in the present study. Therefore, further studies with an
increased number of patients are necessary. Also, the quality of CEUS examinations and thus
Fig 1. Comparison of all perfusion parameters. Significant differences were only observed for Peak (up left) when comparing the
center of the lesion (center column) versus the surrounding liver tissue (left column) center of the lesion vs. its margins (right colum).
https://doi.org/10.1371/journal.pone.0217599.g001
Fig 2. Pre-interventional evaluation for peak enhancement. A. Before embolization, the tumor and margin area show a
profound enhancement in CEUS original images. B. In pseudo-colors the tumor is displayed in red colors. C. TIC analyses show
that the perfusion curve for the center of the lesion (green) has a profound rise and fall consistent with a HCC.
https://doi.org/10.1371/journal.pone.0217599.g002
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Fig 3. Case of successful TACE (display of peak enhancement). A. After the intervention, the post-embolization defect in CEUS
original images appears black, meaning nearly avascular. B. In pseudo-colors the defect is shown in blue colors, also showing a
devascularization. C. TIC analyses show that the perfusion curve for the center of the defect (green) is close to the baseline.
https://doi.org/10.1371/journal.pone.0217599.g003
Fig 4. Case of a partially successful TACE (display of peak enhancement). A. The post-embolization defect in CEUS original
images shows residual contrast enhancement, consistent with remaining tumor. B. In pseudo-colors the defect is shown in blue to
green colors, proving an only partial devascularization. C. TIC analyses show that the perfusion curve for the center of the defect
(green) is not quite close to the baseline confirming residual tumor.
https://doi.org/10.1371/journal.pone.0217599.g004
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VueBox evaluation strongly depends on the localization of the tumor lesion, as lesions in
deeper layers are harder to visualize. Compared to other imaging modalities, CEUS requires
specific technology and an experienced examiner and highly depend on the patient’s compli-
ance regarding breathing and circulation.
However, due to the relatively low costs, compared to imaging modalities such as CT or
MRI ultrasound and CEUS in particular is a valuable tool for repeating post-interventional fol-
low-up examinations. Also, the contrast agents used in CEUS have a reduced risk profile in
comparison to CT and MRI regarding renal and thyroid function and potential allergic risks.
In summary, it can be said that the contrast-enhanced ultrasound in combination with per-
fusion analysis is a valuable supporting tool for post-interventional success control following
TACE of liver lesions.
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